|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yuan Q, Deng D, Pan C, Wei T, Wu Z, Zhang
B, Li S, Yin P and Shang D: Integration of transcriptomics,
proteomics, and metabolomics data to reveal HER2-associated
metabolic heterogeneity in gastric cancer with response to
immunotherapy and neoadjuvant chemotherapy. Front Immunol.
13:9511372022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ribas A and Wolchok JD: Cancer
immunotherapy using checkpoint blockade. Science. 359:1350–1355.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS,
Kumar A, Vishakha Behl T, Jha SK and Tang H: Advancements in
clinical aspects of targeted therapy and immunotherapy in breast
cancer. Mol Cancer. 22:1052023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morad G, Helmink BA, Sharma P and Wargo
JA: Hallmarks of response, resistance, and toxicity to immune
checkpoint blockade. Cell. 184:5309–5337. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
O'Donnell JS, Teng MWL and Smyth MJ:
Cancer immunoediting and resistance to T cell-based immunotherapy.
Nat Rev Clin Oncol. 16:151–167. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dolladille C, Ederhy S, Sassier M, Cautela
J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF,
et al: Immune checkpoint inhibitor rechallenge after immune-related
adverse events in patients with cancer. JAMA Oncol. 6:865–871.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang L, Feng J, Kuang T, Chai D, Qiu Z,
Deng W, Dong K, Zhao K and Wang W: Blood biomarkers predict
outcomes in patients with hepatocellular carcinoma treated with
immune checkpoint Inhibitors: A pooled analysis of 44 retrospective
sudies. Int Immunopharmacol. 118:1100192023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao J, Li D, Xie S, Deng X, Wen X, Li J,
Wu Z, Yang X, Li M, Tang Y, et al: Nomogram for predicting
prognosis of patients with metastatic melanoma after immunotherapy:
A Chinese population-based analysis. Front Immunol. 13:10838402022.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vergnenegre A and Chouaid C: Economic
analyses of immune-checkpoint inhibitors to treat lung cancer.
Expert Rev Pharmacoecon Outcomes Res. 21:365–371. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schalper KA, Carleton M, Zhou M, Chen T,
Feng Y, Huang SP, Walsh AM, Baxi V, Pandya D, Baradet T, et al:
Elevated serum interleukin-8 is associated with enhanced intratumor
neutrophils and reduced clinical benefit of immune-checkpoint
inhibitors. Nat Med. 26:688–692. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Wang K, Kuang T, Deng W, Hu P and
Wang W: Low geriatric nutritional risk index as a poor prognostic
biomarker for immune checkpoint inhibitor treatment in solid
cancer. Front Nutr. 10:12865832023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ren J, Wang A, Liu J and Yuan Q:
Identification and validation of a novel redox-related lncRNA
prognostic signature in lung adenocarcinoma. Bioengineered.
12:4331–4348. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Havel JJ, Chowell D and Chan TA: The
evolving landscape of biomarkers for checkpoint inhibitor
immunotherapy. Nat Rev Cancer. 19:133–150. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Forrest LM, McMillan DC, McArdle CS,
Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic
scores based on the systemic inflammatory response in patients with
inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Proctor MJ, Morrison DS, Talwar D, Balmer
SM, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC: An
inflammation-based prognostic score (mGPS) predicts cancer survival
independent of tumour site: A glasgow inflammation outcome study.
Br J Cancer. 104:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagashima Y, Funahashi K, Kagami S,
Ushigome M, Kaneko T, Miura Y, Yoshida K, Koda T and Kurihara A:
Which preoperative immunonutritional index best predicts
postoperative mortality after palliative surgery for malignant
bowel obstruction in patients with late-stage cancer? A
single-center study in Japan comparing the modified Glasgow
prognostic score (mGPS), the prognostic nutritional index (PNI),
and the controlling nutritional status (CONUT). Surg Today.
53:22–30. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schuettfort VM, Gust K, D'Andrea D, Quhal
F, Mostafaei H, Laukhtina E, Mori K, Rink M, Abufaraj M,
Karakiewicz PI, et al: Impact of the preoperative modified glasgow
prognostic score on disease outcome after radical cystectomy for
urothelial carcinoma of the bladder. Minerva Urol Nephrol.
74:302–312. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hsueh SW, Liu KH, Hung CY, Kuo YC, Tsai
CY, Hsu JT, Hung YS, Tsang NM and Chou WC: Significance of the
glasgow prognostic score in predicting the postoperative outcome of
patients with stage III gastric cancer. J Clin Med. 8:14482019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vashist YK, Loos J, Dedow J, Tachezy M,
Uzunoglu G, Kutup A, Yekebas EF and Izbicki JR: Glasgow prognostic
score is a predictor of perioperative and long-term outcome in
patients with only surgically treated esophageal cancer. Ann Surg
Oncol. 18:1130–1138. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamada S, Fujii T, Yabusaki N, Murotani K,
Iwata N, Kanda M, Tanaka C, Nakayama G, Sugimoto H, Koike M, et al:
Clinical implication of inflammation-based prognostic score in
pancreatic cancer: Glasgow prognostic score is the most reliable
parameter. Medicine (Baltimore). 95:e35822016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shimoyama R, Imamura Y, Uryu K, Mase T,
Ohtaki M, Ohtani K, Shiragami M, Fujimura Y, Hayashi M, Shinozaki N
and Minami H: Inflammation-based prognostic markers in patients
with advanced or recurrent gastric cancer treated with nivolumab:
Tokushukai REAl-world Data project 02 (TREAD 02). Mol Clin Oncol.
21:902024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Diker O and Olgun P: Association of the
immune-inflammation-nutritional parameters with immune checkpoint
inhibitor outcomes in patients with advanced non-small cell lung
cancer. J Oncol Sci. 8:43–53. 2022. View Article : Google Scholar
|
|
25
|
Yamamoto Y, Matsuyama H, Matsumoto H,
Sakano S, Fuji N, Oba K, Yamamoto M, Kamiryo Y, Hiragino T, Nagao
K, et al: Prognostic value of risk stratification using blood
parameters for nivolumab in Japanese patients with metastatic
renal-cell carcinoma. Jpn J Clin Oncol. 50:214–220. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Freitas C, Jacob M, Tavares N,
Cruz-Martins N, Souto-Moura C, Araújo D, Novais-Bastos H, Santos V,
Fernandes G, Magalhães A, et al: Modified glasgow prognostic score
predicts survival among advanced non-small cell lung carcinoma
patients treated with anti-PD1 agents. Anticancer Drugs.
32:567–574. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Ma W, Qiu Z, Kuang T, Wang K, Hu
B and Wang W: Prognostic nutritional index as a prognostic
biomarker for gastrointestinal cancer patients treated with immune
checkpoint inhibitors. Front Immunol. 14:12199292023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang L, Li X, Wang K, Wu M, Liu W and
Wang W: Prognostic impact of body composition in hepatocellular
carcinoma patients with immunotherapy. Ann Med. 56:23950622024.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang L, Xia Z, Li Z, Zhang J, Wang K and
Wang W: Influence of body fat tissue on outcomes in patients
undergoing hepatectomy or liver transplantation. Int J Surg.
111:1167–1181. 2024.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ali WAS, Hui P, Ma Y, Wu Y, Zhang Y, Chen
Y, Hong S, Yang Y, Huang Y, Zhao Y, et al: Determinants of survival
in advanced non-small cell lung cancer patients treated with
anti-PD-1/PD-L1 therapy. Ann Transl Med. 9:16392021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Araki T, Tateishi K, Sonehara K, Hirota S,
Komatsu M, Yamamoto M, Kanda S, Kuraishi H, Hanaoka M and Koizumi
T: Clinical utility of the C-reactive protein:albumin ratio in
non-small cell lung cancer patients treated with nivolumab. Thorac
Cancer. 12:603–612. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brown JT, Liu Y, Shabto JM, Martini D,
Ravindranathan D, Hitron EE, Russler GA, Caulfield S, Yantorni L,
Joshi SS, et al: Modified glasgow prognostic score associated with
survival in metastatic renal cell carcinoma treated with immune
checkpoint inhibitors. J Immunother Cancer. 9:e0028512021.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brown JT, Liu Y, Shabto JM, Martini DJ,
Ravindranathan D, Hitron EE, Russler GA, Caulfield S, Yantorni LB,
Joshi SS, et al: Baseline modified glasgow prognostic score
associated with survival in metastatic urothelial carcinoma treated
with immune checkpoint inhibitors. Oncologist. 26:397–405. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chikuie N, Hamamoto T, Ueda T, Taruya T,
Kono T, Furuie H, Ishino T and Takeno S: Baseline
neutrophil-to-lymphocyte ratio and glasgow prognostic score are
associated with clinical outcome in patients with recurrent or
metastatic head and neck squamous cell carcinoma treated with
nivolumab. Acta Med Okayama. 75:335–343. 2021.PubMed/NCBI
|
|
35
|
Fujiwara R, Takemura K, Fujiwara M, Yuasa
T, Yasuoka S, Komai Y, Numao N, Yamamoto S and Yonese J: Modified
glasgow prognostic score as a predictor of prognosis in metastatic
renal cell carcinoma treated with nivolumab. Clin Genitourin
Cancer. 19:e78–e83. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Imai H, Kishikawa T, Minemura H, Yamada Y,
Ibe T, Yamaguchi O, Mouri A, Hamamoto Y, Kanazawa K, Kasai T, et
al: Pretreatment glasgow prognostic score predicts survival among
patients with high PD-L1 expression administered first-line
pembrolizumab monotherapy for non-small cell lung cancer. Cancer
Med. 10:6971–6984. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kang HS, Shin AY, Yeo CD, Kim SK, Park CK,
Kim JS, Kim SJ, Lee SH and Kim JW: Significance of glasgow
prognostic scores in NSCLC patients treated with immunotherapy
after platinum-based cytotoxic chemotherapy. In Vivo. 35:3423–3430.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kasahara N, Sunaga N, Tsukagoshi Y, Miura
Y, Sakurai R, Kitahara S, Yokobori T, Kaira K, Mogi A, Maeno T, et
al: Post-treatment glasgow prognostic score predicts efficacy in
advanced non-small-cell lung cancer treated with anti-PD1.
Anticancer Res. 39:1455–1461. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kasajima M, Igawa S, Manaka H, Yamada K,
Akazawa Y, Manabe H, Yagami Y, Yamamoto H, Ito H, Kaizuka N, et al:
The glasgow prognostic score predicts outcomes of pembrolizumab or
atezolizumab monotherapy in patients with pretreated non-small cell
lung cancer. Oncology. 101:69–76. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kawakami H, Sunakawa Y, Inoue E, Matoba R,
Noda K, Sato T, Suminaka C, Yamaki M, Sakamoto Y, Kawabata R, et
al: Soluble programmed cell death ligand 1 predicts prognosis for
gastric cancer patients treated with nivolumab: Blood-based
biomarker analysis for the DELIVER trial. Eur J Cancer. 184:10–20.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kurosaki T, Kawakami H, Mitani S, Kawabata
R, Takahama T, Nonagase Y, Fumita S, Ozaki T, Chiba Y, Tamura T and
Nakagawa K: Glasgow prognostic score (GPS) and tumor response as
biomarkers of nivolumab monotherapy in third- or later-line setting
for advanced gastric cancer. In Vivo. 34:1921–1929. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Madeddu C, Busquets S, Donisi C, Lai E,
Pretta A, López-Soriano FJ, Argilés JM, Scartozzi M and Macciò A:
Effect of cancer-related cachexia and associated changes in
nutritional status, inflammatory status, and muscle mass on
immunotherapy efficacy and survival in patients with advanced
non-small cell lung cancer. Cancers (Basel). 15:10762023.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Matsubara T, Takamori S, Haratake N,
Toyozawa R, Miura N, Shimokawa M, Yamaguchi M, Seto T and
Takenoyama M: The impact of immune-inflammation-nutritional
parameters on the prognosis of non-small cell lung cancer patients
treated with atezolizumab. J Thorac Dis. 12:1520–1528. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Matsuki T, Okamoto I, Fushimi C, Sawabe M,
Kawakita D, Sato H, Tsukahara K, Kondo T, Okada T, Tada Y, et al:
Hematological predictive markers for recurrent or metastatic
squamous cell carcinomas of the head and neck treated with
nivolumab: A multicenter study of 88 patients. Cancer Med.
9:5015–5024. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Matsuo M, Yasumatsu R, Masuda M, Toh S,
Wakasaki T, Hashimoto K, Jiromaru R, Manako T and Nakagawa T:
Inflammation-based prognostic score as a prognostic biomarker in
patients with recurrent and/or metastatic head and neck squamous
cell carcinoma treated with nivolumab therapy. In Vivo. 36:907–917.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Minichsdorfer C, Gleiss A, Aretin MB,
Schmidinger M and Fuereder T: Serum parameters as prognostic
biomarkers in a real world cancer patient population treated with
anti PD-1/PD-L1 therapy. Ann Med. 54:1339–1349. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Minohara K, Matoba T, Kawakita D, Takano
G, Oguri K, Murashima A, Nakai K, Iwaki S, Hojo W, Matsumura A, et
al: Novel prognostic score for recurrent or metastatic head and
neck cancer patients treated with nivolumab. Sci Rep. 11:169922021.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mortensen REJ, Holmström MO, Lisle TL,
Hasselby JP, Willemoe GL, Met Ö, Marie Svane I, Johansen J, Nielsen
DL, Chen IM and Andersen MH: Pre-existing TGF-β-specific T-cell
immunity in patients with pancreatic cancer predicts survival after
checkpoint inhibitors combined with radiotherapy. J Immunother
Cancer. 11:e0064322023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Namikawa T, Yokota K, Tanioka N, Fukudome
I, Iwabu J, Munekage M, Uemura S, Maeda H, Kitagawa H, Kobayashi M
and Hanazaki K: Systemic inflammatory response and nutritional
biomarkers as predictors of nivolumab efficacy for gastric cancer.
Surg Today. 50:1486–1495. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Niwa K, Kawakita D, Nagao T, Takahashi H,
Saotome T, Okazaki M, Yamazaki K, Okamoto I, Hirai H, Saigusa N, et
al: Multicentre, retrospective study of the efficacy and safety of
nivolumab for recurrent and metastatic salivary gland carcinoma.
Sci Rep. 10:169882020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Noguchi G, Nakaigawa N, Umemoto S,
Kobayashi K, Shibata Y, Tsutsumi S, Yasui M, Ohtake S, Suzuki T,
Osaka K, et al: C-reactive protein at 1 month after treatment of
nivolumab as a predictive marker of efficacy in advanced renal cell
carcinoma. Cancer Chemother Pharmacol. 86:75–85. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ogura Y, Kataoka N, Kunimatsu Y, Tachibana
Y, Sugimoto T, Tani N, Sato I, Hirose K, Kato D and Takeda T:
Predictors of survival among Japanese patients receiving first-line
chemoimmunotherapy for advanced non-small cell lung cancer. Thorac
Cancer. 12:97–105. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sakai D, Omori T, Fumita S, Fujita J,
Kawabata R, Matsuyama J, Yasui H, Hirao M, Kawase T, Kishi K, et
al: Real-world effectiveness of third- or later-line treatment in
Japanese patients with HER2-positive, unresectable, recurrent or
metastatic gastric cancer: A retrospective observational study. Int
J Clin Oncol. 27:1154–1163. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tada T, Kumada T, Hiraoka A, Kariyama K,
Tani J, Hirooka M, Takaguchi K, Atsukawa M, Fukunishi S, Itobayashi
E, et al: New prognostic system based on inflammation and liver
function predicts prognosis in patients with advanced unresectable
hepatocellular carcinoma treated with atezolizumab plus
bevacizumab: A validation study. Cancer Med. 12:6980–6993. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Takamori S, Takada K, Shimokawa M,
Matsubara T, Fujishita T, Ito K, Toyozawa R, Yamaguchi M, Okamoto
T, Yoneshima Y, et al: Clinical utility of pretreatment glasgow
prognostic score in non-small-cell lung cancer patients treated
with immune checkpoint inhibitors. Lung Cancer. 152:27–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tanaka T, Yoshida T, Masuda K, Takeyasu Y,
Shinno Y, Matsumoto Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N
and Ohe Y: Prognostic role of modified glasgow prognostic score in
elderly non-small cell lung cancer patients treated with anti-PD-1
antibodies. Respir Investig. 61:74–81. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tokuyama N, Takegawa N, Nishikawa M, Sakai
A, Mimura T, Kushida S, Tsumura H, Yamamoto Y, Miki I and Tsuda M:
Pretreatment glasgow prognostic score as a predictor of outcomes in
nivolumab-treated patients with advanced gastric cancer. PLoS One.
16:e02476452021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ueki Y, Takahashi T, Ota H, Shodo R,
Yamazaki K and Horii A: Predicting the treatment outcome of
nivolumab in recurrent or metastatic head and neck squamous cell
carcinoma: Prognostic value of combined performance status and
modified Glasgow prognostic score. Eur Arch Otorhinolaryngol.
277:2341–2347. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wasamoto S, Imai H, Tsuda T, Nagai Y,
Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, et
al: Pretreatment glasgow prognostic score predicts survival among
patients administered first-line atezolizumab plus carboplatin and
etoposide for small cell lung cancer. Front Oncol. 12:10807292023.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yamamoto Y, Yatsuda J, Shimokawa M, Fuji
N, Aoki A, Sakano S, Yamamoto M, Suga A, Tei Y, Yoshihiro S, et al:
Prognostic value of pre-treatment risk stratification and
post-treatment neutrophil/lymphocyte ratio change for pembrolizumab
in patients with advanced urothelial carcinoma. Int J Clin Oncol.
26:169–177. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yang Z, Zhang D, Zeng H, Fu Y, Hu Z, Pan
Y, Chen J, Wang J, Zhang Y, Zhou Z, et al: Inflammation-based
scores predict responses to PD-1 inhibitor treatment in
intrahepatic cholangiocarcinoma. J Inflamm Res. 15:5721–5731. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zaitsu J, Yamashita Y, Ishikawa A, Saito
A, Kagimoto A, Mimura T, Hirakawa T, Mito M, Fukuhara K, Senoo T,
et al: Systemic inflammatory score predicts response and prognosis
in patients with lung cancer treated with immunotherapy. Anticancer
Res. 41:3673–3682. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Takegawa N, Hirabayashi T, Tanaka S,
Nishikawa M, Tokuyama N, Mimura T, Kushida S, Tsumura H, Yamamoto
Y, Miki I and Tsuda M: The impact of nutritional status in
nivolumab-treated patients with advanced esophageal cancer. PLoS
One. 18:e02853652023. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tanaka K, Hirakawa H, Suzuki M, Higa T,
Agena S, Hasegawa N, Kawakami J, Toyama M, Higa T, Kinjyo H, et al:
Biomarkers for predicting anti-programmed cell death-1 antibody
treatment effects in head and neck cancer. Curr Oncol.
30:5409–5424. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhang Y, Chen S, Chen H and Li W: A
comprehensive analysis of glasgow prognostic score (GPS)/the
modified glasgow prognostic score (mGPS) on immune checkpoint
inhibitor efficacy among patients with advanced cancer. Cancer Med.
12:38–48. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wu J, Wang H, Yang R, Liu D and Li W:
Prognostic significance of the modified Glasgow Prognostic Score in
NSCLC patients undergoing immune checkpoint inhibitor therapy: A
meta-analysis. Front Oncol. 14:14498532024. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Wang H, Yang R, Cheng C, Wang S, Liu D and
Li W: Prognostic value of the glasgow prognostic score in non-small
cell lung cancer patients receiving immunotherapy: A meta-analysis.
Nutr Cancer. 76:187–195. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Yao ZH, Tian GY, Yang SX, Wan YY, Kang YM,
Liu QH, Yao F and Lin DJ: Serum albumin as a significant prognostic
factor in patients with malignant pleural mesothelioma. Tumour
Biol. 35:6839–6845. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Gupta D and Lis CG: Pretreatment serum
albumin as a predictor of cancer survival: A systematic review of
the epidemiological literature. Nutr J. 9:692010. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Miura K, Hamanaka K, Koizumi T, Kitaguchi
Y, Terada Y, Nakamura D, Kumeda H, Agatsuma H, Hyogotani A,
Kawakami S, et al: Clinical significance of preoperative serum
albumin level for prognosis in surgically resected patients with
non-small cell lung cancer: Comparative study of normal lung,
emphysema, and pulmonary fibrosis. Lung Cancer. 111:88–95. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Yang J, Petersen CE, Ha CE and Bhagavan
NV: Structural insights into human serum albumin-mediated
prostaglandin catalysis. Protein Sci. 11:538–545. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
China L, Maini A, Skene SS, Shabir Z,
Sylvestre Y, Colas RA, Ly L, Becares Salles N, Belloti V, Dalli J,
et al: Albumin counteracts immune-suppressive effects of lipid
mediators in patients with advanced liver disease. Clin
Gastroenterol Hepatol. 16:738–747.e7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Choe WH and Baik SK: Prostaglandin
E2-mediated immunosuppression and the role of albumin as its
modulator. Hepatology. 61:1080–1082. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Arroyo V and Moreau R: Tying up PGE2 with
albumin to relieve immunosuppression in cirrhosis. Nat Med.
20:467–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Du Clos TW and Mold C: C-reactive protein:
An activator of innate immunity and a modulator of adaptive
immunity. Immunol Res. 30:261–277. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Nozoe T, Matsumata T and Sugimachi K:
Preoperative elevation of serum C-reactive protein is related to
impaired immunity in patients with colorectal cancer. Am J Clin
Oncol. 23:263–266. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Abramovitch R, Marikovsky M, Meir G and
Neeman M: Stimulation of tumour growth by wound-derived growth
factors. Br J Cancer. 79:1392–1398. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Canna K, Hilmy M, McMillan DC, Smith GW,
McKee RF, McArdle CS and McNicol AM: The relationship between
tumour proliferative activity, the systemic inflammatory response
and survival in patients undergoing curative resection for
colorectal cancer. Colorectal Dis. 10:663–667. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Coffelt SB and de Visser KE: Cancer:
Inflammation lights the way to metastasis. Nature. 507:48–49. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Bito R, Hino S, Baba A, Tanaka M, Watabe H
and Kawabata H: Degradation of oxidative stress-induced denatured
albumin in rat liver endothelial cells. Am J Physiol Cell Physiol.
289:C531–C542. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wu J, Ding P, Wu H, Yang P, Guo H, Tian Y,
Meng L and Zhao Q: Sarcopenia: Molecular regulatory network for
loss of muscle mass and function. Front Nutr. 10:10372002023.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Condeelis J and Pollard JW: Macrophages:
Obligate partners for tumor cell migration, invasion, and
metastasis. Cell. 124:263–266. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Ding P, Guo H, He X, Sun C, Lowe S,
Bentley R, Zhou Q, Yang P, Tian Y, Liu Y, et al: Effect of skeletal
muscle loss during neoadjuvant imatinib therapy on clinical
outcomes in patients with locally advanced GIST. BMC Gastroenterol.
22:3992022. View Article : Google Scholar : PubMed/NCBI
|
